Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OGA | O60502 | 2/20 | 0.45 |
| ▸ | GPR119 | Q8TDV5 | 14/20 | 0.45 |
| ▸ | NPC1 | O15118 | 2/20 | 0.39 |
| ▸ | RAB9A | P51151 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.38 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19434401 | 1.00 | OGA (0.45) | OGAGPR119NPC1RAB9AKDM4E | |
| SCHEMBL19434276 | 1.00 | OGA (0.45) | OGAGPR119NPC1RAB9AKDM4E | |
| SCHEMBL19434339 | 0.88 | KDM4E (0.52) | GPR119NPC1RAB9AKDM4E | |
| SCHEMBL19434393 | 0.88 | KDM4E (0.52) | GPR119NPC1RAB9AKDM4E | |
| SCHEMBL19450847 | 0.88 | KDM4E (0.52) | GPR119NPC1RAB9AKDM4E | |
| SCHEMBL19450729 | 0.87 | OGA (0.47) | OGAGPR119NPC1RAB9AKDM4E | |
| SCHEMBL19457226 | 0.84 | GPR119 (0.50) | OGAGPR119NPC1RAB9AKDM4E | |
| SCHEMBL19450640 | 0.83 | GPR119 (0.44) | OGAGPR119NPC1RAB9AKDM4E | |
| SCHEMBL19449870 | 0.83 | GPR119 (0.44) | OGAGPR119NPC1RAB9AKDM4E | |
| SCHEMBL1103982 | 0.83 | MAPK8 (0.47) | OGAGPR119NPC1RAB9AKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10954229-B2 | GPR119 agonist compounds | MANKIND PHARMA LTD. (IN) | 2021-03-23 | — | — | US | disclosed |
| US-20200317661-A1 | NOVEL GPR119 AGONIST COMPOUNDS | MANKIND PHARMA LTD. (IN) | 2020-10-08 | — | — | US | disclosed |
| US-10752622-B2 | GPR119 agonist compounds | MANKIND PHARMA LTD. (IN) | 2020-08-25 | — | — | US | disclosed |
| US-20190127363-A1 | NOVEL GPR119 AGONIST COMPOUNDS | MANKIND PHARMA LTD. (IN) | 2019-05-02 | — | — | US | disclosed |
| US-10208030-B2 | GPR119 agonist compounds | MANKIND PHARMA LTD. (IN) | 2019-02-19 | — | — | US | disclosed |
| US-20170291894-A1 | NOVEL GPR119 AGONIST COMPOUNDS | MANKIND PHARMA LTD. (IN) | 2017-10-12 | — | — | US | disclosed |
| US-20170291894-A1 | NOVEL GPR119 AGONIST COMPOUNDS | MANKIND PHARMA LTD. (IN) | 2017-10-12 | — | — | US | disclosed |
| WO-2017175066-A1 | HETEROCYCLIC GPR119 AGONIST COMPOUNDS | MANKIND PHARMA LTD. (IN) | 2017-10-12 | — | — | WO | disclosed |
| WO-2011147951-A1 | CYCLOAMINO DERIVATIVES AS GPR119 ANTAGONISTS | PROSIDION LIMITED (GB) | 2011-12-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200317661-A1 | NOVEL GPR119 AGONIST COMPOUNDS | GPR119, GPR84, GPR88 | OGA 3394/4885GPR119 1/4885NPC1 842/4885 |
| US-20170291894-A1 | NOVEL GPR119 AGONIST COMPOUNDS | GPR119, GPR84, GPR88 | OGA 3394/4885GPR119 1/4885NPC1 842/4885 |
| US-10752622-B2 | GPR119 agonist compounds | GPR119, GPR84, GPR65 | OGA 2895/4885GPR119 1/4885NPC1 685/4885 |
| US-10954229-B2 | GPR119 agonist compounds | GPR119, GPR84, GPR65 | OGA 2895/4885GPR119 1/4885NPC1 685/4885 |
| US-10208030-B2 | GPR119 agonist compounds | GPR119, GPR84, GPR65 | OGA 2895/4885GPR119 1/4885NPC1 685/4885 |
| US-20190127363-A1 | NOVEL GPR119 AGONIST COMPOUNDS | GPR119, GPR84, GPR88 | OGA 3394/4885GPR119 1/4885NPC1 842/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.